Merck & Co. concluded negotiations to acquire Revolution Medicines after failing to agree on a valuation that reportedly approached $30 billion. Sources indicate that Merck maintained strict discipline on deal size despite both companies’ shared focus on RAS-pathway oncology therapies. The termination of talks underlines Merck’s cautious approach to M&A in the high-growth cancer drug sector and signals heightened investor scrutiny of biotech valuations.

During the most recent SEC reporting period, Cullen/Frost Bankers Inc. reduced its Merck stake by 7.0%, selling 17,082 shares and trimming its position to 225,581 shares. Meanwhile, Charles Schwab Investment Management added 4.6 million shares in the second quarter, increasing its holding to 53.9 million shares. New entrants such as DLD Asset Management LP and Norges Bank established positions worth approximately $2.9 billion and $2.86 billion, respectively, reflecting a broader institutional reallocation within Merck’s shareholder base.

In its latest quarterly report, Merck posted earnings per share of $1.94, missing consensus estimates by $0.14. The company reported a 29.6% net margin and a return on equity of 44.5%. Analysts forecast full-year EPS of approximately $9.01, supported by strong sales of its oncology and vaccine portfolio. Merck’s debt-to-equity ratio stands at 0.77, while liquidity measures remain solid, with a current ratio of 1.66 and quick ratio of 1.44.

Merck recently raised its quarterly dividend by $0.04 to $0.85 per share, marking a 5.0% increase and extending its dividend growth streak. The updated annualized payout of $3.40 yields roughly 3.1%, with a payout ratio near 45%. This enhancement underscores Merck’s commitment to returning capital amidst ongoing investment in R&D and strategic portfolio expansion.